Holen Sie sich die Stockscreener-App
17.53
0.17%
0.03
Handel nachbörslich:
17.53
Schlusskurs vom Vortag:
$17.50
Offen:
$17.36
24-Stunden-Volumen:
292.29K
Relative Volume:
0.41
Marktkapitalisierung:
$777.98M
Einnahmen:
$9.00M
Nettoeinkommen (Verlust:
$-80.61M
KGV:
-7.8147
EPS:
-2.2432
Netto-Cashflow:
$-82.35M
1W Leistung:
+10.74%
1M Leistung:
-13.60%
6M Leistung:
+211.37%
1J Leistung:
+432.83%
1-Tages-Spanne:
$17.05
$17.75
1-Wochen-Bereich:
$16.02
$18.31
52-Wochen-Spanne:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
17.53 | 776.65M | 9.00M | -80.61M | -82.35M | -2.2432 |
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.26 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.92 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.82 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
559.65 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Needham | Buy |
| 2026-02-25 | Eingeleitet | Oppenheimer | Outperform |
| 2026-02-18 | Hochstufung | Jefferies | Hold → Buy |
| 2026-01-27 | Eingeleitet | Piper Sandler | Overweight |
| 2025-12-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
Sectors Review: Can BioAge Labs Inc expand its profit marginsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
BioAge Labs (BIOA) CMO Rubin sells $157k in shares - Investing.com UK
BioAge Labs (BIOA) CMO Rubin sells $157k in shares By Investing.com - Investing.com India
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 8,820 shares at $17.81 - stocktitan.net
Risk Hedge: How do insiders feel about BioAge Labs IncWeekly Profit Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
BIOA PE Ratio & Valuation, Is BIOA Overvalued - Intellectia AI
Short Covering: Can BioAge Labs Inc lead its sector in growthWeekly Earnings Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
BGE-102 data inspires confidence for BioAge Labs (BIOA) - MSN
Paul Rubin reports three 7,433-share sales (BIOA) in Form 144 - stocktitan.net
BioAge Labs, Inc. (BIOA) stock price, news, quote and history - Yahoo Finance UK
BioAge Labs (NASDAQ:BIOA) Shares Up 8.7%Here's Why - marketbeat.com
BGE-102 Data Inspires Confidence for BioAge Labs (BIOA) - insidermonkey.com
Market Trends: Can BioAge Labs Inc expand its profit marginsTreasury Yields & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Street Watch: Whats the beta of BioAge Labs Inc stock2026 EndofMonth & Weekly Top Stock Performers List - baoquankhu1.vn
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
BioAge Labs (NASDAQ:BIOA) Shares Gap UpStill a Buy? - marketbeat.com
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com
BioAge Labs (NASDAQ:BIOA) Coverage Initiated at Needham & Company LLC - marketbeat.com
Needham Initiates BioAge Labs at Buy With $50 Price Target - marketscreener.com
Needham Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $50 - Moomoo
Needham initiates coverage of BioAge Labs (BIOA) with buy recommendation - MSN
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating - TipRanks
BioAge Highlights BGE-102 Progress and Financial Strength - The Globe and Mail
Earnings Update: How correlated is BioAge Labs Inc to the S P5002026 Fed Impact & Short-Term Trading Alerts - baoquankhu1.vn
Price Action: Can BioAge Labs Inc. lead its sector in growth2026 Review & High Accuracy Trade Alerts - baoquankhu1.vn
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 By Investing.com - Investing.com Australia
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress By Investing.com - Investing.com India
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress - Investing.com
BioAge Labs (NASDAQ: BIOA) registers shelf for future equity and debt offers - Stock Titan
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 - Investing.com
BioAge Labs Full-Year 2025 Net Loss Narrows - Moomoo
BioAge Labs (NASDAQ:BIOA) Stock Price Down 9.8%Here's Why - MarketBeat
BioAge Labs Provides Business Updates - Lifespan Research Institute
BioAge Labs Reports Positive 2025 Financial Results and Advances BGE-102 NLRP3 Inhibitor Toward Phase 2 Trials in Cardiovascular and Ophthalmology Indications - Minichart
BioAge Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
BioAge Labs 2025-2026 Pipeline: Advancing BGE-102 NLRP3 Inhibitor for Cardiometabolic Disease and Ophthalmology Based on Aging Biology Insights - Minichart
BIOAGE Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Form 10-K BioAge Labs, Inc. For: Dec 31 - StreetInsider
BioAge Labs (NASDAQ: BIOA) boosts R&D and outlines cash runway to 2029 - Stock Titan
Earnings Flash (BIOA) BioAge Labs Posts 2025 Collaboration Revenue $9M, vs. FactSet Est of $7.1M - marketscreener.com
Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss - marketscreener.com
Earnings Flash (BIOA) BioAge Labs Posts 2025 Collaboration Revenue $9M, Vs. FactSet Est of $7.1M - Moomoo
BioAge Labs (NASDAQ: BIOA) widens 2025 loss but extends cash runway to 2029 - Stock Titan
BioAge Labs full-year collaboration revenue beats estimates - TradingView
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 - ChartMill
BIOA Stock Price, Quote & Chart | BIOAGE LABS INC (NASDAQ:BIOA) - ChartMill
BioAge Labs, Inc.(NasdaqGS: BIOA) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Certain Warrant of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
35,850,037 Stock Options of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
Certain Common Stock of BioAge Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioage Labs Inc-Aktie (BIOA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Sale |
17.81 |
8,820 |
157,084 |
0 |
1.35%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):